For the year ending 2025-12-31, KRRO had -$33,819K decrease in cash & cash equivalents over the period. -$79,079K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -117,260 |
| Non-cash lease expense | 730 |
| Stock-based compensation expense | 7,655 |
| Depreciation expense | 4,280 |
| Long-lived asset impairment charge | 30,886 |
| Net amortization of premiums and discounts on marketable securities | 489 |
| Loss on disposal of property and equipment | -63 |
| Accounts receivable | -727 |
| Prepaid expenses and other current assets | 1,674 |
| Accounts payable | -2,311 |
| Accrued expenses and other current liabilities | 1,431 |
| Deferred revenue | -1,590 |
| Operating lease liabilities | -1,279 |
| Other non-current assets | -270 |
| Net cash used in operating activities | -78,561 |
| Purchases of marketable securities | 26,189 |
| Proceeds from maturities of marketable securities | 70,700 |
| Purchases of property and equipment | 518 |
| Net cash provided by (used in) investing activities | 43,993 |
| Proceeds from pipe financing, net of issuance costs | 0 |
| Proceeds from exercises of stock options | 685 |
| Net cash provided by financing activities | 685 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 64 |
| Net decrease in cash, cash equivalents and restricted cash | -33,819 |
| Cash, cash equivalents and restricted cash, beginning of period | 59,049 |
| Cash, cash equivalents and restricted cash, end of period | 25,230 |
Korro Bio, Inc. (KRRO)
Korro Bio, Inc. (KRRO)